Full-Time

Senior Scientist

Machine Learning and Protein Design

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$185k - $195kAnnually

+ Bonus + Equity Grant

Senior

North Bethesda, MD, USA

Relocation assistance is offered if required.

Category
Applied Machine Learning
Deep Learning
AI & Machine Learning
Requirements
  • PhD in computer science, computational biology, structural biology, synthetic biology, biophysics, bioinformatics or related discipline.
  • Demonstrated expertise in generative AI and deep learning algorithms, frameworks, associated programming languages and systems architecture.
  • The ability to independently design, build and evaluate ML models.
  • Expertise in state-of-the-art protein design applications such as Rosetta, AlphaFold2, RoseTTAFold, RFdiffusion, ProteinMPNN, etc.
  • Strong working knowledge of protein developability considerations for therapeutic proteins.
  • Able to work collaboratively and communicate effectively in interdisciplinary teams.
Responsibilities
  • Lead and collaborate with an interdisciplinary team of scientists to design and evaluate novel proteins and de novo biological systems in support of therapeutic programs.
  • Implement and develop ML-based, protein design solutions for structure prediction, paratope/epitope analysis, affinity maturation, developability assessment, scaffold optimization, library design, immunogenicity and other protein engineering challenges.
  • Communicate progress and project recommendations in one-on-ones, project teams and company-wide meetings.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

18%

1 year growth

24%

2 year growth

72%
Simplify Jobs

Simplify's Take

What believers are saying

  • The Phase 3 iMMagine-3 trial for anito-cel could significantly boost Arcellx's market position if successful.
  • Recent robust long-term responses from the Phase 1 expansion trial of anito-cel indicate promising efficacy and safety, potentially leading to FDA approval.
  • The $285M equity investment and upfront cash from Kite provide substantial financial backing for Arcellx's ongoing and future projects.

What critics are saying

  • The competitive landscape for CAR T therapies is intense, with established players like Abecma and Carvykti posing significant challenges.
  • Regulatory hurdles, such as the recent FDA partial hold, could delay product development and market entry.

What makes Arcellx unique

  • Arcellx's anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T therapy for multiple myeloma utilizing a novel D-Domain binder, setting it apart from existing treatments.
  • The company's strategic partnership with Kite, a Gilead Company, enhances its research capabilities and market reach, distinguishing it from smaller biotech firms.
  • Arcellx's focus on innovative immunotherapies for cancer and other incurable diseases positions it uniquely in the biotech landscape.

Help us improve and share your feedback! Did you find this helpful?